Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹13 Cr
P/E Ratio
--
P/B Ratio
-9.26
Industry P/E
35.02
Debt to Equity
-0.54
ROE
0 %
ROCE
0 %
Div. Yield
0 %
Book Value
-2.75
EPS
-1.43
CFO
₹0.24 Cr
EBITDA
₹-2.34 Cr
Net Profit
₹-0.33 Cr
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Venmax Drugs
| 41.30 | -1.47 | 0.39 | -- | -- | -- | 12.51 |
|
BSE Healthcare
| -5.48 | 1.35 | 0.22 | 22.74 | 20.05 | 23.06 | 9.77 |
|
BSE Small Cap
| -10.07 | 4.18 | -3.21 | 7.10 | 18.99 | 35.87 | 15.84 |
|
2015
|
2014
|
|
|---|---|---|
|
Venmax Drugs
| -20.92 | -73.58 |
|
BSE Small Cap
| 6.76 | 69.24 |
|
BSE Healthcare
| 15.06 | 47.43 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | P/E Ratio | ROE |
|---|---|---|---|---|
| 737.00 | 6,679.32 | 26.79 | 13.8 | |
| 2,202.50 | 9,011.72 | 74.24 | 12.96 | |
| 416.90 | 5,141.64 | 68.95 | 6.24 | |
| 913.45 | 5,221.77 | 40.99 | 14.76 |
No Review & Analysis are available.
Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable... alkaloids; Read more
Incorporated
1988
Chairman
--
Managing Director
--
Headquarters
Hyderabad, Telangana
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The total asset value of Venmax Drugs And Pharmaceuticals Ltd stood at ₹ 1 Cr as on 31-Dec-24
The share price of Venmax Drugs And Pharmaceuticals Ltd is ₹25.49 (BSE) as of 23-Apr-2025 IST. Venmax Drugs And Pharmaceuticals Ltd has given a return of --% in the last 1 years.
Venmax Drugs And Pharmaceuticals Ltd has a market capitalisation of ₹ 13 Cr as on 23-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Venmax Drugs And Pharmaceuticals Ltd is -9.26 times as on 23-Apr-2025, a 347% discount to its peers’ median range of 3.75 times.
Since, TTM earnings of Venmax Drugs And Pharmaceuticals Ltd is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Venmax Drugs And Pharmaceuticals Ltd and enter the required number of quantities and click on buy to purchase the shares of Venmax Drugs And Pharmaceuticals Ltd.
Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids;
The promoter of Venmax Drugs And Pharmaceuticals Ltd is VENKAT NARENDER NUKA. VENKAT NARENDER NUKA owns 17.69 per cent of the total equity. The chairman of the company is ..
There is no promoter pledging in Venmax Drugs And Pharmaceuticals Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
9,512
|
|
|
6,653
|
|
|
5,320
|
|
|
5,217
|
| Venmax Drugs And Pharmaceuticals Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
-181.65
|
|
Net Margin(%)
|
-123.88
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Venmax Drugs And Pharmaceuticals Ltd was ₹-1 Cr.
₹-0.52
(
